China
Epigenic Therapeutics is a pioneering biotechnology company that focuses on the development of next generation gene editing therapy using epigenetic genome regulation for various diseases. Founded in 2021 by leading scientists, the company boasts a robust pipeline with multiple product candidates, including treatments for metabolic, cardiovascular, viral hepatitis, ocular, and rare diseases.
Based in China, the company recently secured a significant $32.00M Series A investment on 29 August 2023 from prominent investors such as Qiming Venture Partners, OrbiMed, and Morningside Venture Investments.
Epigenic Therapeutics' focus on cutting-edge gene editing technologies and potential therapies positions it as a promising player in the biotechnology industry, making it an attractive prospect for venture capital investors seeking high-growth opportunities in the evolving healthcare landscape.
